Association of amniotic fluid Neurotrophins levels with intrauterine growth restriction

Nikolaos Machairiotis¹, Vasilios Pergialiotis², Konstantinos Vlassis³, Theodoros Troupis³, Nikolaos Vrachnis¹

¹ 3rd Department of Obstetrics and Gynecology, Attikon Hospital, National and Kapodistrian University of Athens, Greece
² 1st Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, “Alexandra” General Hospital, Athens, Greece
³ Department of Anatomy, School of Medicine, faculty of health sciences, national and Kapodistrian University of Athens

Corresponding Author
Nikolaos Machairiotis, 3rd Department of Obstetrics and Gynecology, Attikon Hospital, National and Kapodistrian University of Athens, Greece, e-mail: nikolaosmachairiotis@gmail.com

Abstract
Neurotrophins have been previously mentioned as potential factors that may alter human growth and result in fetal growth restriction (FGR). As neural growth factors, neurotrophins promote brain development and plasticity and have a significant effect on the synaptic transmission, although the actual mechanisms of their action have not been completely investigated. Several articles have been published in this field denoting the importance of neurotrophins as biomarkers of detection of fetuses with fetal growth restriction. Their findings are contradictory and the purpose of the present systematic review is to summarize existing evidence and provide recommendations for future research.

Key words: Neyrotrophin, growth restriction

Introduction
Fetal growth restriction (FGR) is a relatively common antenatal pathology that is encountered in approximately 3-7% of pregnancies¹ and refers to the inability of the fetus to retain its genetically attributed growth potential. Several factors contribute to the occurrence of FGR including congenital infections, malnutrition, anemia and chronic diabetes mellitus.² Two distinct subgroups of FGR are identified, namely the asymmetrical FGR which refers to the majority (70-80%) of cases and the symmetrical group which is encountered in 20-30% of pregnancies complicated by the condition.³ The asymmetrical form of FGR is identified during late pregnancy and is mainly the result of disproportionate growth of the fetus which preserves the central fetal blood flow, therefore, enabling brain growth, together
reducing the blood flow to the liver and reducing the abdominal circumference. Most cases that are complicated by asymmetrical FGR have already developed preeclampsia and the reduced blood flow that is observed in the context of altered vasculogenesis may significantly impair placental oxygen uptake.\(^4\) The symmetrical form, although less prevalent, is significantly more complex as it refers to conditions that affect pregnancy during the first trimester and results in complex antenatal and postnatal pathology that is the result of the condition that affected the intrauterine growth.

Several mechanisms have been proposed as potential pathophysiological triggering factors of FGR, however, still several gaps exist that require further investigation. Among those, neurotrophins have been previously proposed as potential factors that may alter human growth and result in FGR.\(^5\) These proteins are well known growth factors that are primarily expressed in the brain, but can be identified in peripheral tissues as well.\(^6,7\) As neural growth factors, neurotrophins promote brain development and plasticity and have a significant effect on the synaptic transmission, although the actual mechanisms of their action have not been completely investigated.\(^8\) Four proteins comprise the neurotrophin family, namely the brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), NT-3, and NT-4. It is believed that they modulate several functions as their action relies in two distinct receptors; the Trk and the p75 receptor, an effect that is believed to allow an increased degree of freedom in terms of neural modulation. Specifically, the activation of the Trk pathway seems to promote cell survival, whereas activation of the p75 receptor induces apoptosis, as this receptor is a member of the tumor necrosis factor (TNF) receptor family (Figure).\(^9\)

Research in the field of antenatal pathology remains to date relatively rare, although there are scarce reports that suggest an association with growth restriction. Of note, previous researchers indicated that NGF is important during the early stages of placental development as it is expressed by cytotrophoblasts, syncytiotrophoblasts, chorionic mesodermal cells and decidual cells.\(^10\) In the present

---

**Figure 1.**
Neurotrophin expression in FGR

communication letter we summarize the available evidence that correlates neurotrophins with fetal growth restriction and provide directions for future research.

**Methods**

**Design and eligibility criteria**

To detect new studies published after the publication of the previous systematic review we systematically searched the literature considering current recommendations of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Eligibility criteria for the inclusion of studies were predetermined. We chose to include observational studies and randomized trials that compared differences in the expression of neurotrophins as well as potential gene polymorphisms that may affect their functionality among cases with FGR and healthy control pregnancies. The review was designed to include all studies that were published in the Medline (1966–2023), Scopus (2004–2023), Clinicaltrials.gov (2008–2023), EMBASE (1980-2023), Cochrane Central Register of Controlled Trials CENTRAL (1999-2023) databases. The date of last search was set at February, 15th 2023.

**Results**

Evidence related to the significant contribution of human placental neurotrophic factors on fetal development has been derived since 2013 by Dhoebale et al who described that preterm fetuses have significantly lower mRNA expression of Brain-derived neurotrophic factor (BDNF) in placental tissue as well as lower level of nerve growth factor (NGF). They also observed that despite the lack of a correlation of those proteins with preterm delivery, a positive association between mRNA levels and protein expression was evident, therefore, leading to the assumption of a potential correlation that could not be detected due to the small sample size that was used. They also attributed their findings to potential epigenetic differences compared to control placentas that were retrieved from pregnancies delivered at term and underlined the potential implications of altered fetal programming.

It should be noted that the expression of neurotrophins in the placental varies significantly among its different regions, as, according to Sahay et al their levels are significantly higher in the central fetal region compared to the central maternal and peripheral fetal/maternal region. Taking this information into consideration it becomes easily understandable that maternal levels of those cytokines does not necessarily reflect the fetal levels, and more importantly gaps in the available research may be attributed to the lack of standardized methodology in the uptake of those proteins.

Noting this, it becomes easily understandable that a direct extrapolation of these findings to fetal growth restriction should not be regarded as prudent, evidence from Malamitsi-Puchner et al suggests that the levels of NGF in term fetal growth restricted fetuses are significantly lower compared to term fetuses of average birthweight for their gestational age (AGA). Of note, in this study the levels of neurotrophins were measured in neonates and their mothers at day 1 and 4 and no correlation with growth restriction was observed in BDNF, NT-3 and NT-4 among FGR and AGA cases.

Amniotic fluid levels reflect better the actual intravascular fetal levels of cytokines. In this context Antonakopoulos et al observed the association between BDNF levels in amniotic fluid during the second trimester of pregnancy and fetal development and observed significant differences among severely growth restricted fetuses (<3 percentile) compared to AGA fetuses. Even the evaluation of amniotic fluid levels of neurotrophins is not, however, entirely free of bias as Flock et al reported that high
maternal BMI and low maternal blood BDNF may
differentiate the limit of detection of amniotic fluid
BDNF throughout gestation.\textsuperscript{17}

Possibly the best way to observe potential dif-
fferences among growth restricted and AGA fetuses
is to review cord blood levels of neurotrophins. To
date, this has been investigated only in term preg-
nancies by Briana et al in pregnancies complicated
by gestational diabetes mellitus with the authors
mentioning the absence of a specific correlation
with fetal growth percentiles.\textsuperscript{18}

It remains relatively unknown how these differ-
ences in neurotrophin levels among normal and
growth restricted infants may hinder human develop-
ment and specifically neurodevelopment as current
evidence remains extremely scarce. Richter et al
observed altered methylations in the neurodevelop-
mental DNA among fetal growth restricted fetuses
that were subject to brain-sparing.\textsuperscript{19} Specifically, the
authors reported significant hypermethylation at
a binding site for cyclic adenosine monophosphate
response element binding protein (CREB) of BDNF
promoter exon 4 and hypomethylation at an HRE
located within the neurotrophic tyrosine kinase,
receptor, type 2 (NTRK2) promoter.

This information seems to be very important as
it may guide future research by helping to establish
therapeutic models in growth restricted fetuses.
Experimental studies suggest that supplementation
with taurine, a naturally occurring sulfur-containing
amino acid that enhances neural growth, increased
the ratio neurons to glial cells and prevented gliosis
in the differentiation of neural stem cells.\textsuperscript{20,21} The
whole process was mediated by the protein kinase
A-cyclic adenosine monophosphate (cAMP) and
the response element protein-brain derived neurotrophic
factor (PKA-CREB-BDNF) signaling pathway.

\textbf{Conclusion}

Neurotrophins seem to play an important role
in embryo development, an effect that is equally
distributed during three trimesters of pregnancy. To
date, evidence correlating these proteins with fetal
growth restriction remains scarce and extremely heterogeneous; hence, it remains unknown if they
may serve as predictive factors during early preg-
nancy, or even if they may become targets of future
therapeutic strategies, as indicated by experimental
animal studies. Future research must focus in spe-
cific populations, including those with gestational
diabetes mellitus and preeclampsia, as their expres-
sion seems to significantly differentiate compared to
healthy pregnancies. Moreover, investigation of the
actual site to be targeted from future researchers is
necessary as current knowledge indicates differences
in expression even among samples from different
placental locations.

\textbf{Disclosure}

The authors report no conflict of interest

\textbf{Funding}

None to disclose for all authors.

\textbf{References}

1. Romo A, Carceller R, Tobajas J. Intrauterine
growth retardation (IUGR): epidemiology and
etiology. Pediatr Endocrinol Rev 2009;6 Suppl
3(332-6
2. Maulik D. Fetal growth restriction: the etiol-
doi:10.1097/00003081-200606000-00006
3. Shrivastava D, Master A. Fetal Growth Restric-
tion.] Obstet Gynaecol India 2020;70(2):103-110,
doi:10.1007/s13224-019-01278-4
4. Maulik D. Fetal growth compromise: defini-
tions, standards, and classification. Clin
Obstet Gynecol 2006;49(2):214-8, doi:
10.1097/00003081-200606000-00004
5. Sahay A, Kale A, Joshi S. Role of neurotrophins
Neurotrophin expression in FGR


Received 26-04-23
Revised 02-05-23
Accepted 05-05-23